Five-year Results of the PERLE Implant in Breast Augmentation and Augmentation-Mastopexy
Aesthetic Surgery Journal · 15.04.2026
DOI: 10.1093/asj/sjag074 ↗Kurz gefasst
Fachartikel in der Zeitschrift Aesthetic Surgery Journal, online erschienen am 15.04.2026. Verfasst von James Lucocq und 1 weiteren Autor:innen. Beteiligte Einrichtung: Edinburgh Breast Unit, Western General Hospital, Edinburgh, UK. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Advances in the manufacturing of breast implants through improved shell architecture, gel cohesivity, and surface topography may mitigate postoperative complications following breast augmentation.
Objectives
The present study aims to report 5-year results of the PERLE implant (GC Aesthetics, Dublin, Ireland), which is a round breast implant with an average surface roughness of 5 μm that was launched in 2020.
Methods
A retrospective cohort study was performed including consecutive patients undergoing primary or secondary bilateral breast augmentation and augmentation-mastopexy with PERLE implants between December 2020 and December 2025. The primary outcomes were implant-related complications and reoperation over 5 years. Outcomes were analyzed per patient and per implant.
Results
In all, 738 patients (augmentation, n = 592; augmentation-mastopexy, n = 146) receiving 1476 implants were followed for up to 5 years (median follow-up, 34 months). Implant-related complications occurred in 2.8% of patients overall: 2.2% (13/592) following augmentation and 5.5% (8/146) following augmentation-mastopexy. The per-patient rate of capsular contracture was 0.5% following augmentation (n = 3) and 0.7% following augmentation-mastopexy (n = 1). Per implant, the overall rate of capsular contracture was 0.3% (subglandular, 0.4% [2/476]; dual-plane, 0.3% [2/690]; subfascial, 0.0% [0/296]; and submuscular, 0.0% [0/14]). The rate of implant malposition was 0.7% and 1.4% per implant inserted, following augmentation and augmentation-mastopexy, respectively. The 1-year, 3-year, and 5-year reoperation rate for implant-related complications was 1.2%, 2.1%, and 2.5%, respectively in the augmentation group. No cases of implant rupture, rippling, or breast implant–associated anaplastic large cell lymphoma (BIA-ALCL) were reported.
Conclusions
At 5 years, breast augmentation and augmentation-mastopexy with the PERLE implant demonstrated low rates of capsular contracture, implant malposition, and implant-related reoperation. Level of Evidence: 4 (Therapeutic) For image description, please refer to the figure legend and surrounding text.
Autor:innen und Institutionen
- Edinburgh Breast Unit, Western General Hospital, Edinburgh, UK.
- Consultant plastic surgeon in private practice in Glasgow, UK.
ORCID-Profile: James Lucocq
Zitieren
APA
Lucocq, J., & Shoaib, T. (2026). Five-year Results of the PERLE Implant in Breast Augmentation and Augmentation-Mastopexy. Aesthetic Surgery Journal. https://doi.org/10.1093/asj/sjag074
Vancouver
Lucocq J, Shoaib T. Five-year Results of the PERLE Implant in Breast Augmentation and Augmentation-Mastopexy. Aesthetic Surgery Journal. 2026. doi:10.1093/asj/sjag074
BibTeX
@article{Lucocq2026,
author = {Lucocq, James and Shoaib, Taimur},
title = {Five-year Results of the PERLE Implant in Breast Augmentation and Augmentation-Mastopexy},
journal = {Aesthetic Surgery Journal},
year = {2026},
doi = {10.1093/asj/sjag074}
}
EUVIMED